Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06198309
Other study ID # al123456
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2023
Est. completion date December 1, 2027

Study information

Verified date December 2023
Source Beijing Chao Yang Hospital
Contact Li An
Phone CHN+13681133265
Email bjzy818@sina.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.


Recruitment information / eligibility

Status Recruiting
Enrollment 365
Est. completion date December 1, 2027
Est. primary completion date December 1, 2027
Accepts healthy volunteers
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading ? - ? (FEV1/FVC<70%, FEV1% predicted value = 50% after Bronchiectasis) 2. Age>40 years old 3. COPD stable for more than 4 weeks 4. Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month 5. Patient informed and signed consent form Exclusion Criteria: 1. Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis 2. Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease) 3. History of chronic diarrhea or constipation 4. History of Gastrointestinal Surgery 5. Using probiotics or antibiotics within the past 4 weeks 6. No history of using oral hormones or traditional Chinese medicine in the past three months 7. Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Chaoyang Hospital Affiliated to Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Li An

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the predictive performance of the COPD frequent seizure risk prediction model based on the area under the ROC curve. According to the Area Under Curve (AUC) of ROC, the largest one has the best predictive performance. When AUC>0.5, the closer it is to 1, the better the predictive performance of the model. When AUC=0.5, it indicates poor model fitting and no potential predictive value. A year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03923660 - Ventilatory Adaptation to Concentric Versus Eccentric Exercise in Patients With Severe COPD N/A
Recruiting NCT06008210 - A Decision Aid on End-of-life Care for Patients With Advanced COPD and Their Family N/A
Recruiting NCT05029349 - Exploration of the VOLATOLOM in the Stable Severe COPD (Chronic Obstructive Pulmonary Disease) N/A
Not yet recruiting NCT05539547 - Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD Early Phase 1
Recruiting NCT04018729 - Cell Therapy Associated With Endobronchial Valve Phase 2/Phase 3
Suspended NCT04848012 - Efficacy of an Advanced Auto-titrating NIV in COPD N/A
Recruiting NCT03398772 - Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease. N/A
Recruiting NCT06247397 - Effect of HIgh-flow Therapy in Long-term Oxygen Therapy N/A
Completed NCT05259280 - Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD N/A
Not yet recruiting NCT06212765 - Oral Citrulline Supplementation in COPD Patients With Malnutrition Phase 3
Completed NCT02962999 - Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Phase 4
Not yet recruiting NCT06229509 - Study of the Cytokine Response During Exercise Dyspnea in Patients With Chronic Obstructive Pulmonary Disease (COPD). Effect of Body Composition N/A
Completed NCT05431218 - Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD Phase 4
Recruiting NCT04069312 - Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE) Phase 4
Recruiting NCT05575336 - Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients N/A
Completed NCT02998515 - Effects of Different Oxygen Devices in Hypoxemic COPD Patients N/A
Completed NCT04533516 - Additional Manual Therapy Over Inspiratory Muscle Training in COPD N/A
Recruiting NCT06072690 - Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease